EARLY DISEASE CLEARANCE WITH ETRASIMOD AND CORRELATION WITH WEEK 52 OUTCOMES AND BIOMARKERS: A POST HOC ANALYSIS OF THE PHASE 3 ELEVATE UC TRIALS
Fernando Magro 1
Laurent Peyrin-Biroulet 2, 3
Bruce E. Sands 4
Silvio Danese 5
Vipul Jairath 6
Martina Goestch 7
Abhishek Bhattacharjee 8
Joseph Wu 9
Diogo Branquinho 10
Irene Modesto 11
1 University of Porto and Centro Hospitalar São João, Porto, Portugal
2 University of Lorraine, CHRU-Nancy, Nancy, France
3 University of Lorraine, Inserm, NGERE, Nancy, France
4 Icahn School of Medicine at Mount Sinai, New York, United States
5 IRCCS San Raffaele Hospital and Vita Salute San Raffaele University, Milan, Italy
6 Western University, London, Canada
7 Pfizer AG, Zürich, Switzerland
8 Pfizer Healthcare India Pvt. Ltd, Chennai, India
9 Pfizer Inc, Groton, United States
10 Pfizer Inc, New York, United States
11 Pfizer Inc, Madrid, Spain
Topic
IBD
Session
Traffic control in IBD
Conference
UEG Week 2023
Citation
United European Gastroenterology Journal 2023; 11 (Supplement 8)
Login to access library content
Do you need help setting up your myUEG account?
Contact us at [email protected]